Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements

This article was originally published in The Pink Sheet Daily

Executive Summary

Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.

You may also be interested in...

The Skinny On Labeling For Orexigen’s Contrave

The biotech finally gains approval for its obesity agent and receives a label from FDA that, despite multiple contraindications and a boxed warning, is being looked upon favorably.

FDA Panel To Weigh Relevance Of Liraglutide’s Diabetes Experience In Obesity

Agency will ask external advisors Sept. 11 how the GLP-1 agonist’s safety in type 2 diabetes, approved as Victoza in 2010, informs the safety profile in obesity, where Novo Nordisk is seeking a higher dose and a different name.

The Nissen/Fleming Solution For ‘Firewalled’ CV Data Disclosures

Framework described by Cleveland Clinic’s Nissen specifies which employees within a sponsor have access to detailed interim results from outcomes trials and the recordkeeping requirements and technology restrictions associated with that access.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts